Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Blood disorders Stories

2012-07-09 02:25:05

WHITE PLAINS, N.Y., July 9, 2012 /PRNewswire/ -- Over the past decade, Burlington Coat Factory has raised close to $13 million through its company-wide initiative encouraging its customers to purchase paper balloon icons as a donation to The Leukemia & Lymphoma Society (LLS) to help fund cancer research and patient services, Today, Burlington Coat Factory, LLS's #1 National Corporate Light The Night(®) Walk partner, announced the launch of its 11th year in support of the campaign....

2012-07-09 02:24:27

SAN DIEGO, July 9, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has received Investigational Review Board (IRB) approval at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center for a Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of cutaneous T-cell...

2012-07-08 22:21:10

PARIS, July 9, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds. Edward Gomperts, MD, Attending...

2012-07-07 22:20:15

WAYNE, N.J., July 8, 2012 /PRNewswire/ -- Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A. The PROTECT VIII (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII) trial is designed to investigate whether BAY94-9027, a recombinant human factor VIII (rFVIII), can prolong the duration of protection from bleeds and allow...

2012-07-06 23:03:42

New study “Global Hemophilia Market Report: 2012 Edition” developed by Koncept Analytics has been recently published by Market Publishers Ltd. According to the study, the global market for hemophilia products has shown continuous growth in the past years growing at 8.96% CAGR from 2006 to 2011 and is projected to expand steadily in the upcoming years. London, UK (PRWEB) July 06, 2012 The global market for hemophilia products has shown continuous growth in the past years growing...

2012-07-05 10:22:42

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies. About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although bone marrow stem cell transplantation is an option for some, patients without a matched donor have few treatment options....

2012-07-03 06:25:27

YPSILANTI, Mich., July 3, 2012 /PRNewswire-USNewswire/ -- The Hemophilia Foundation of Michigan (HFM) has named its Michigan Legislators of the Year. The annual awards, which recognize excellence in legislative policy making affecting the bleeding disorders community, were announced at HFM's annual consumer conference. Presenting the legislative awards, Hemophilia Foundation of Michigan Executive Director, Ivan Harner, noted, "Senator Tonya Schuitmaker recognizes the life long issues that...

2012-07-02 21:54:39

Findings could yield therapies against these serious blood diseases and related cancers Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. "Researchers have suspected that...

2012-07-02 06:25:10

WHITE PLAINS, N.Y. and PRINCETON, N.J., July 2, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society® (LLS) and Celator Pharmaceuticals, Inc. today announced a significant expansion of their partnership to support clinical development and potential registration of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML). Under the new agreement, LLS will provide $5 million in funding, through its...

2012-07-01 18:20:20

Findings Could Yield Therapies Against These Serious Blood Diseases and Related Cancers BRONX, N.Y., July 2, 2012 /PRNewswire-USNewswire/ -- Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent...